Related Experiment Videos

The myth of 'stable' coronary artery disease

Keith A A Fox1, Marco Metra2, João Morais3

  • 1British Heart Foundation Centre for Cardiovascular Sciences, University of Edinburgh, Edinburgh, UK. k.a.a.fox@ed.ac.uk.

Insights

The term "stable" coronary artery disease (CAD) is misleading, as patients face ongoing risks of cardiovascular events due to plaque and systemic factors. A "vulnerable patient" approach better addresses these long-term risks and guides new therapies.

Area of Science:

  • Cardiology
  • Vascular Medicine
  • Atherothrombosis Research

Background:

  • Patients with known cardiovascular disease (CVD) are often labeled with "stable" coronary artery disease (CAD).
  • This "stable" classification is misleading due to persistent risks of cardiovascular events and diverse risk characteristics.
  • Current secondary prevention strategies, including lifestyle changes and medical therapies, do not eliminate these ongoing risks.

Purpose of the Study:

  • To challenge the misconception of "stable" CAD.
  • To explore the pathophysiology of CAD, emphasizing plaque and systemic factors in cardiovascular events.
  • To advocate for a "vulnerable patient" concept to better assess and manage long-term atherothrombotic risks.

Main Methods:

  • Review of the pathophysiology of coronary artery disease.
  • Analysis of plaque and systemic factors contributing to cardiovascular events.
  • Evaluation of current and emerging medical therapies for chronic atherothrombotic disease.

Main Results:

  • The concept of "stable" CAD underestimates long-term cardiovascular event risks.
  • Both plaque characteristics and systemic factors significantly contribute to atherothrombotic events.
  • A "vulnerable patient" perspective is crucial for understanding diverse and future risks.

Conclusions:

  • Coronary artery disease is rarely "stable" and carries persistent risks.
  • A paradigm shift towards identifying the "vulnerable patient" is necessary.
  • Further research into novel medical therapies is essential for reducing cardiovascular events in patients with chronic CAD.

Related Concept Videos